TBPH
Theravance Biopharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$863.02M
P/E Ratio
8.14
EPS
$2.06
Beta
0.17
52W High
$21.03
52W Low
$8.33
50-Day MA
$16.10
200-Day MA
$15.87
Dividend Yield
—
Profit Margin
98.50%
Forward P/E
7.86
PEG Ratio
-0.05
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.
Fundamentals
| Revenue (TTM) | $107.46M |
| Gross Profit (TTM) | $70.05M |
| EBITDA | $-1.98M |
| Operating Margin | 43.60% |
| Return on Equity | 44.90% |
| Return on Assets | -0.54% |
| Revenue/Share (TTM) | $2.14 |
| Book Value | $5.81 |
| Price-to-Book | 2.92 |
| Price-to-Sales (TTM) | 8.03 |
| EV/Revenue | 5.52 |
| EV/EBITDA | 4.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 144.70% |
| Shares Outstanding | $51.49M |
| Float | $24.13M |
| % Insiders | 3.95% |
| % Institutions | 98.04% |
Historical Volatility
HV 10-Day
26.46%
HV 20-Day
31.93%
HV 30-Day
28.81%
HV 60-Day
71.42%
HV Rank
16.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($17.20 target)
3
Buy4
HoldData last updated: 4/29/2026